Response to Mahe

Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer

“…20,30,31 Published clinical response data for two of these discordant cases have shown the patients to have a positive response to treatment with crizotinib. 30,31 We acknowledge the limited number of samples in our study resulting in sub-optimal statistical power and the potential for artificially high concordance rates due to the low number of ALK and ROS1-positive cases as previously discussed in regards to Selinger et al 20,32,33 Therefore, further studies with a larger number of cases is required to confirm and validate our results along with our proposed testing algorithm. However, the results from our study still provide relevant data for selecting the most appropriate testing methods in the detection of ALK and ROS1 rearrangements to guide treatment selection for patients with NSCLC.…”